4Moving Biotech Closes Euros 12M Financing for Knee OA Program
4Moving Biotech (4MB), a clinical-stage biotechnology company and a spin-off of 4P-Pharma, developing a first-in-class disease-modifying osteoarthritis drug (DMOAD) for knee osteoarthritis, announced on February 10th the closing of a €12 million financing, completed through a structured and coordinated funding process. This financing was secured from a pool of private investors and family offices, who […]
